Global Retirement Partners LLC Sells 340 Shares of Exact Sciences Co. (NASDAQ:EXAS)

Global Retirement Partners LLC reduced its position in shares of Exact Sciences Co. (NASDAQ:EXAS) by 3.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 8,379 shares of the medical research company’s stock after selling 340 shares during the quarter. Global Retirement Partners LLC’s holdings in Exact Sciences were worth $471,000 at the end of the most recent reporting period.

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Huntington National Bank lifted its position in Exact Sciences by 838.1% during the third quarter. Huntington National Bank now owns 394 shares of the medical research company’s stock valued at $27,000 after purchasing an additional 352 shares during the last quarter. RPg Family Wealth Advisory LLC bought a new position in shares of Exact Sciences in the 3rd quarter valued at about $34,000. Capital Performance Advisors LLP purchased a new position in Exact Sciences in the third quarter worth about $35,000. Asset Planning Inc bought a new stake in Exact Sciences during the fourth quarter worth approximately $40,000. Finally, Modus Advisors LLC purchased a new stake in Exact Sciences during the fourth quarter valued at approximately $43,000. 88.82% of the stock is owned by hedge funds and other institutional investors.

Exact Sciences Stock Down 0.5 %

Shares of NASDAQ EXAS opened at $49.26 on Monday. The stock has a market capitalization of $9.15 billion, a PE ratio of -8.84 and a beta of 1.24. The company has a current ratio of 2.15, a quick ratio of 1.93 and a debt-to-equity ratio of 0.97. Exact Sciences Co. has a 12-month low of $40.62 and a 12-month high of $79.62. The stock’s fifty day simple moving average is $54.91 and its two-hundred day simple moving average is $60.04.

Exact Sciences (NASDAQ:EXAS) last posted its earnings results on Wednesday, February 19th. The medical research company reported ($0.06) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.29) by $0.23. The company had revenue of $713.42 million for the quarter, compared to analyst estimates of $701.45 million. Exact Sciences had a negative return on equity of 5.29% and a negative net margin of 37.29%. As a group, analysts expect that Exact Sciences Co. will post -0.58 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of brokerages have recently commented on EXAS. Barclays dropped their target price on Exact Sciences from $70.00 to $65.00 and set an “overweight” rating for the company in a report on Thursday. Craig Hallum cut their price objective on shares of Exact Sciences from $82.00 to $65.00 and set a “buy” rating on the stock in a research report on Wednesday, November 6th. The Goldman Sachs Group lowered their target price on shares of Exact Sciences from $75.00 to $65.00 and set a “buy” rating for the company in a report on Wednesday, November 6th. Bank of America cut their price target on shares of Exact Sciences from $72.00 to $65.00 and set a “buy” rating on the stock in a report on Thursday. Finally, Sanford C. Bernstein raised their price objective on shares of Exact Sciences from $75.00 to $90.00 and gave the stock an “outperform” rating in a research note on Wednesday, October 30th. One investment analyst has rated the stock with a hold rating and eighteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, Exact Sciences has an average rating of “Moderate Buy” and an average target price of $72.06.

Exact Sciences Profile

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services.